tetano
Editor, Senior Moderator
Cytokine Growth Factor Rev
. 2023 Mar 5;S1359-6101(23)00012-6.
doi: 10.1016/j.cytogfr.2023.03.001. Online ahead of print.
Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
Lidong Wang[SUP] 1 [/SUP], Michelle Møhlenberg[SUP] 2 [/SUP], Pengfei Wang[SUP] 3 [/SUP], Hao Zhou[SUP] 4 [/SUP]
Affiliations
Abstract
Since its emergence at the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the infection of more than 600 million people worldwide and has significant damage to global medical, economic, and political structures. Currently, a highly mutated variant of concern, SARS-CoV-2 Omicron, has evolved into many different subvariants mainly including BA.1, BA.2, BA.3, BA.4/5, and the recently emerging BA.2.75.2, BA.2.76, BA.4.6, BA.4.7, BA.5.9, BF.7, BQ.1, BQ.1.1, XBB, XBB.1, etc. Mutations in the N-terminal domain (NTD) of the spike protein, such as A67V, G142D, and N212I, alter the antigenic structure of Omicron, while mutations in the spike receptor binding domain (RBD), such as R346K, Q493R, and N501Y, increase the affinity for angiotensin-converting enzyme 2 (ACE2). Both types of mutations greatly increase the capacity of Omicron to evade immunity from neutralizing antibodies, produced by natural infection and/or vaccination. In this review, we systematically assess the immune evasion capacity of SARS-CoV-2, with an emphasis on the neutralizing antibodies generated by different vaccination regimes. Understanding the host antibody response and the evasion strategies employed by SARS-CoV-2 variants will improve our capacity to combat newly emerging Omicron variants.
Keywords: Bivalent mRNA vaccine; Booster; Immune evasion; Mutations; Omicron; SARS-CoV-2.
. 2023 Mar 5;S1359-6101(23)00012-6.
doi: 10.1016/j.cytogfr.2023.03.001. Online ahead of print.
Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
Lidong Wang[SUP] 1 [/SUP], Michelle Møhlenberg[SUP] 2 [/SUP], Pengfei Wang[SUP] 3 [/SUP], Hao Zhou[SUP] 4 [/SUP]
Affiliations
- PMID: 36948931
- DOI: 10.1016/j.cytogfr.2023.03.001
Abstract
Since its emergence at the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the infection of more than 600 million people worldwide and has significant damage to global medical, economic, and political structures. Currently, a highly mutated variant of concern, SARS-CoV-2 Omicron, has evolved into many different subvariants mainly including BA.1, BA.2, BA.3, BA.4/5, and the recently emerging BA.2.75.2, BA.2.76, BA.4.6, BA.4.7, BA.5.9, BF.7, BQ.1, BQ.1.1, XBB, XBB.1, etc. Mutations in the N-terminal domain (NTD) of the spike protein, such as A67V, G142D, and N212I, alter the antigenic structure of Omicron, while mutations in the spike receptor binding domain (RBD), such as R346K, Q493R, and N501Y, increase the affinity for angiotensin-converting enzyme 2 (ACE2). Both types of mutations greatly increase the capacity of Omicron to evade immunity from neutralizing antibodies, produced by natural infection and/or vaccination. In this review, we systematically assess the immune evasion capacity of SARS-CoV-2, with an emphasis on the neutralizing antibodies generated by different vaccination regimes. Understanding the host antibody response and the evasion strategies employed by SARS-CoV-2 variants will improve our capacity to combat newly emerging Omicron variants.
Keywords: Bivalent mRNA vaccine; Booster; Immune evasion; Mutations; Omicron; SARS-CoV-2.